Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,368 shares, a decline of 42.7% from the December 15th total of 243,112 shares. Currently, 4.6% of the shares of the stock are sold short. Based on an average trading volume of 82,461 shares, the short-interest ratio is presently 1.7 days. Based on an average trading volume of 82,461 shares, the short-interest ratio is presently 1.7 days. Currently, 4.6% of the shares of the stock are sold short.

Insider Buying and Selling

In other Exicure news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $8.71, for a total value of $3,774,321.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 52.80% of the company’s stock.

Exicure Trading Up 1.2%

NASDAQ XCUR opened at $6.00 on Thursday. Exicure has a 1 year low of $3.10 and a 1 year high of $15.91. The stock’s 50-day moving average price is $5.18 and its two-hundred day moving average price is $5.48. The company has a market cap of $38.22 million, a PE ratio of -1.62 and a beta of 4.06.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Exicure has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.